Research Papers:

Prognostic value of transglutaminase 2 in non-small cell lung cancer patients

Zhu Chihong, Ling Yutian, Wan Danying, Jiang Ruibin, Sheng Huaying, Gu Linhui _ and Feng Jianguo

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:45577-45584. https://doi.org/10.18632/oncotarget.17374

Metrics: PDF 1434 views  |   HTML 2261 views  |   ?  


Zhu Chihong1,*, Ling Yutian1,*, Wan Danying1, Jiang Ruibin1, Sheng Huaying1, Gu Linhui1,2 and Feng Jianguo1,2

1Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China

2Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China

*These authors have contributed equally to this work

Correspondence to:

Gu Linhui, email: [email protected]

Feng Jianguo, email: [email protected]

Keywords: TG2, NSCLC, prognosis

Abbreviations: TG2: Transglutaminase 2; NSCLC: non-small cell lung cancer

Received: November 23, 2016     Accepted: February 20, 2017     Published: April 24, 2017


Transglutaminase 2 (TG2) plays important roles in cell survival and cancer progression. In this study, we examined TG2 expression in specimen of 194 patients diagnosed with non-small cell lung cancer (NSCLC), and found that the TG2 gene expression was significantly higher in lung cancer tissues as compared to paired incisal marginal tissues or normal tissues. Our data revealed that patients with lower level of TG2 expression detected in cancer tissues had longer disease free survival and overall survival as compared to the patients with higher TG2 expression. We also found that TG2 expression level correlated to NSCLC recurrence. These results suggest a potential prognosis impact of TG2 for NSCLC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17374